Communiqués Dr. Reddy's Laboratories Limited NSE India S.E.

Actions

DRREDDY

INE089A01023

Produits pharmaceutiques

Marché Fermé - NSE India S.E. Autres places de cotation 13:05:08 07/08/2026			Varia. 5j.	Varia. 1 janv.
1 172,00 ^INR	+0,09%		+2,08%	-7,82%

06/08	Les actions asiatiques cotées aux États-Unis sous forme d'ADR progressent lors de la séance de jeudi	MT
05/08	Les actions asiatiques cotées aux États-Unis sous forme d'ADR progressent lors de la séance de mercredi	MT

Communiqués

04/08	Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States	BU
31/07	Closing a critical treatment gap: New immunotherapy registered in South Africa for recurrent or metastatic nasopharyngeal carcinoma	PU
22/07	Doctor Reddy's: Fiscal Q1 Earnings Snapshot	AQ
22/07	Dr Reddy Laboratories : . Reddy’s Q1FY27 Financial Results	PU
29/06	Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F	AQ
26/06	Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F	BU
22/06	Dr Reddy Laboratories : Life Cycle Assessment Report Consolidated (8 Products) (PwCxDRL Consolidated LCA Report 8 Products Web upload)	PU
13/06	Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States	BU
29/05	Dr Reddy Laboratories : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
16/05	Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada	BU
12/05	Doctor Reddy's: Fiscal Q4 Earnings Snapshot	AQ
12/05	Dr Reddy Laboratories : . Reddy’s Q4 & Full Year FY26 Financial Results	PU
29/04	Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada	BU
29/04	Dr Reddy Laboratories : Announces Health Canada Approval for Generic Semaglutide Injection in Canada	PU
23/02	Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	AQ
20/02	Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept	BU
19/02	Dr Reddy Laboratories : . Reddy’s forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India	PU
06/02	Dr Reddy Laboratories : Landscape Analysis on Alternatives to Animal Testing for Drug Development in India	PU
29/01	Dr Reddy Laboratories : Corporate Governance Report	PU
21/01	Dr Reddy Laboratories : IFRS Consolidated Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Standalone Q3 FY 2025-26	PU
21/01	Dr Reddy Laboratories : INDAS Consolidated Q3 FY 2025-26	PU
21/01	Doctor Reddy's: Fiscal Q3 Earnings Snapshot	AQ
21/01	Dr Reddy Laboratories : . Reddy’s Q3 & 9MFY26 Financial Results	PU
15/01	Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.	AQ